Recently, John Moolenaar, chairman of the House Select Committee on China, urged the U.S. Treasury to add biotech as a prohibited technology under the Comprehensive Outbound Investment National Security Act of 2025, aiming to limit American investment in China's biotech sector. But here's why that might backfire!